TY - JOUR
T1 - Enabling HEK293 cells for antibiotic-free media bioprocessing through CRISPR/Cas9 gene editing
AU - Román, Ramón
AU - Miret, Joan
AU - Roura, Aïda
AU - Casablancas, Antoni
AU - Lecina, Martí
AU - Cairó, Jordi J.
N1 - Funding Information:
The authors would like to thank Dr. A. Kamen (National Research Council of Canada) for kindly providing the HEK293 cells which this work was performed with, and the valuable contribution of Manuela Costa (Institut de Biotecnologia i Biomedicina, UAB) to the FACS analysis and Roger Lahoz (Servei de Genomica i Bioinformatica) to Sanger sequencing.
Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2019/11/15
Y1 - 2019/11/15
N2 - Unlike other cell lines used in industry, HEK293 have not well-established metabolic markers yet for the selection of positive transfected cells expressing recombinant proteins. Three different metabolic markers were explored and assessed in HEK293 to avoid antibiotic-based selection methods. Firstly, PAH gene (Phenylalanine Hydroxylase) was tested as selection marker in tyrosine free medium exploring the potential of the natural tyrosine auxotrophy found in HEK cells. Secondly, two HEK293 mutant cell lines defectives in Thymidylate Synthase (TYMS) and Glutamine Synthetase (GS) were generated using CRISPR/Cas9, and the knocked-out genes were used as selectable markers. Efficiency of selection and eGFP production were evaluated for each selection marker by FACS and compared with the performance based on puromycin selection. Selection efficiencies of 98.60% and 99.95% eGFP + cells were found for PAH and GS selection markers respectively, comparable to puromycin-based selection (99.86% eGFP+). TYMS-based selection system achieved 87.40% eGFP + cells in transfected cultures after one week. Regarding eGFP expression levels, PAH system showed the highest specific production (4,7 × 10−4rfu/cell) followed by GS and puromycin (about 2.0 × 10−4rfu/cell and 2.7 × 10−4rfu/cell, respectively). Inhibitors were then used to increase selection astringency to enhance productivity in selected pools. Eventually, the GS system was used to produce human interferon gamma (hINFγ) as an additional proof of concept. Growth kinetics, advantages and intrinsic limitations of each strategy are assessed and discussed.
AB - Unlike other cell lines used in industry, HEK293 have not well-established metabolic markers yet for the selection of positive transfected cells expressing recombinant proteins. Three different metabolic markers were explored and assessed in HEK293 to avoid antibiotic-based selection methods. Firstly, PAH gene (Phenylalanine Hydroxylase) was tested as selection marker in tyrosine free medium exploring the potential of the natural tyrosine auxotrophy found in HEK cells. Secondly, two HEK293 mutant cell lines defectives in Thymidylate Synthase (TYMS) and Glutamine Synthetase (GS) were generated using CRISPR/Cas9, and the knocked-out genes were used as selectable markers. Efficiency of selection and eGFP production were evaluated for each selection marker by FACS and compared with the performance based on puromycin selection. Selection efficiencies of 98.60% and 99.95% eGFP + cells were found for PAH and GS selection markers respectively, comparable to puromycin-based selection (99.86% eGFP+). TYMS-based selection system achieved 87.40% eGFP + cells in transfected cultures after one week. Regarding eGFP expression levels, PAH system showed the highest specific production (4,7 × 10−4rfu/cell) followed by GS and puromycin (about 2.0 × 10−4rfu/cell and 2.7 × 10−4rfu/cell, respectively). Inhibitors were then used to increase selection astringency to enhance productivity in selected pools. Eventually, the GS system was used to produce human interferon gamma (hINFγ) as an additional proof of concept. Growth kinetics, advantages and intrinsic limitations of each strategy are assessed and discussed.
KW - Glutamine synthetase
KW - HEK293
KW - MSX amplification
KW - Metabolic marker
KW - Phenylalanine hydroxylase
KW - Protein expression
UR - http://www.scopus.com/inward/record.url?scp=85073707304&partnerID=8YFLogxK
U2 - 10.1016/j.bej.2019.107299
DO - 10.1016/j.bej.2019.107299
M3 - Article
AN - SCOPUS:85073707304
SN - 1369-703X
VL - 151
JO - Biochemical Engineering Journal
JF - Biochemical Engineering Journal
M1 - 107299
ER -